REGENXBIO (RGNX) Stock Forecast, Price & News

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO or view top-rated stocks.

Are investors shorting REGENXBIO?

REGENXBIO saw a increase in short interest in April. As of April 30th, there was short interest totaling 3,660,000 shares, an increase of 20.8% from the April 15th total of 3,030,000 shares. Based on an average daily trading volume, of 414,700 shares, the short-interest ratio is currently 8.8 days. Currently, 10.1% of the company's stock are sold short.
View REGENXBIO's Short Interest.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for REGENXBIO.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings data on Tuesday, March, 1st. The biotechnology company reported $6.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.28 by $2.39. The biotechnology company earned $398.66 million during the quarter, compared to analysts' expectations of $255.76 million. REGENXBIO had a net margin of 21.38% and a trailing twelve-month return on equity of 17.92%. The company's revenue was up 1759.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.24) EPS.
View REGENXBIO's earnings history.

What price target have analysts set for RGNX?

7 brokers have issued 12 month target prices for REGENXBIO's stock. Their forecasts range from $17.00 to $82.00. On average, they anticipate REGENXBIO's stock price to reach $47.86 in the next twelve months. This suggests a possible upside of 144.7% from the stock's current price.
View analysts' price targets for REGENXBIO or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:

• Mr. Kenneth T. Mills, Pres, CEO & Director (Age 47, Pay $1.72M)
• Mr. Vittal K. Vasista, Exec. VP & Chief Financial Officer (Age 54, Pay $1.25M)
• Mr. Curran M. Simpson M.S., Exec. VP and Chief Operations & Technology Officer (Age 60, Pay $924.95k)
• Dr. Olivier Danos Ph.D., Exec. VP & Chief Scientific Officer (Age 64, Pay $842.08k)
• Mr. Patrick J. Christmas II, J.D., Exec. VP & Chief Legal Officer (Age 51, Pay $1.11M)
• Ms. Tricia Truehart, VP of Investor Relations & Corp. Communications
• Mr. Andrew Yost, VP of Corp. Devel.
• Ms. Shiva G. Fritsch, Chief People Officer
• Dr. Laura A. Coruzzi J.D., Ph.D., Sr. VP of Intellectual Property (Age 69)
• Mr. Ram Palanki, Sr. VP of Commercial Strategy & Operations

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

Who are some of REGENXBIO's key competitors?

Some companies that are related to REGENXBIO include Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), BioCryst Pharmaceuticals (BCRX), Vaxcyte (PCVX), ImmunityBio (IBRX), Krystal Biotech (KRYS), Immunocore (IMCR) and Valneva (VALN).
View all of RGNX's competitors.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.28%), JPMorgan Chase & Co. (10.95%), Vanguard Group Inc. (9.44%), State Street Corp (6.15%), Dimensional Fund Advisors LP (1.81%) and First Manhattan Co. (1.61%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO.

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., Goldman Sachs Group Inc., Gyon Technologies Capital Management LP, Citigroup Inc., Mirae Asset Global Investments Co. Ltd., Connor Clark & Lunn Investment Management Ltd., and SG Americas Securities LLC. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Kenneth T Mills, Steve Pakola, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was purchased by a variety of institutional investors in the last quarter, including WS Management Lllp, State Street Corp, First Manhattan Co., Assenagon Asset Management S.A., American Century Companies Inc., Jennison Associates LLC, Dimensional Fund Advisors LP, and Los Angeles Capital Management LLC.
View insider buying and selling activity for REGENXBIO or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $19.56.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $843.70 million and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $2.15 on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 372 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].